• Nanoscale proteomic method identifies potential biomarkers.
• Specific isoforms of signaling proteins associated with clinical response to agents that target cancer pathways.
• Nanoscale profiling can help distinguish malignant and non-malignant cells.
DENVER — A novel technology can make nanoscale protein measurements, which scientists can use in clinical trials to learn how drugs work.
“We are making progress toward the goal of understanding how drugs work in different individuals,” said Alice C. Fan, M.D., instructor in the division of oncology at Stanford University School of Medicine. “Using new technologies makes it possible to measure effects of therapeutic agents in tumor cells and different cell populations within our patients. Now that we can make these measurements, we are one step closer to being able to tailor therapy for each patient.”
This research was presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
Currently, research on cancer agent activity requires patients to undergo several invasive biopsies to generate enough cells for testing. Fan and colleagues developed a highly sensitive test called the nano-immunoassay (NIA) that can make nanoscale protein measurements in cells from minimally invasive blood draws or fine-needle aspirates. The researchers used a microfluidic instrument called the Nanopro1000 (Cell Biosciences).
After studying NIA in several clinical trial settings, diagnostic testing results showed that protein profiles in the RAS and MAP kinase pathways could distinguish tumor cells from normal cells. Researchers could use these profiles to group different tumor types.
The researchers analyzed proteins in cells from patients with lymphoma or myelodysplastic syndrome. Two novel treatments for these diseases had a measurable effect on protein activity in tumor cells, Fan said.
Finally, the team used NIA in conjunction with flow cytometry to determine a drug’s differential effects in tumor cells vs. normal cells within each patient.
“These results have immediate application because they can identify which drugs actually hit protein targets in patient cells,” Fan said.
In the long-term, nanoscale approaches may eventually affect all stages of cancer care.
“The ability to make meaningful protein measurements using minute quantities of tissue will allow for earlier discovery of tumors, characterization of small amounts of residual disease and detection of recurrence,” Fan said.
NIA could be particularly useful in studying rare cell populations such as circulating tumor cells and cancer stem cells.
# # #
Follow the AACR on Twitter: @AACR #AACR
Follow the AACR on Facebook: http://www.facebook.com/aacr.org
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world’s oldest and largest professional organization dedicated to advancing cancer research. The membership includes 32,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards. The AACR Annual Meeting attracts more than 18,000 participants who share the latest discoveries and developments in the field. Special Conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. The AACR publishes six major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists, providing a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship and advocacy.
Media Contact:
Jeremy Moore
(267) 646-0557
In Denver, Sept. 27-30:
(303) 352-2464
